Overview of nanoparticle albumin-bound paclitaxel in metastatic breast cancer

By Strauch Demetria Ileana   Moreno-Aspitia Alvaro  

Breast Cancer Management, Vol. 2, Iss. 3, 2013-05 ,pp. : 221-229

Future Medicine

Access to resources Recommend Favorite

Should adjuvant trastuzumab be offered in very early-stage (pT1a/bN0M0) HER2- neu -positive breast cancer? A current debate

By Petrelli Fausto  

Medical Oncology, Vol. 28, Iss. 2, 2011-06 ,pp. : 401-408

Humana Press, Inc

Access to resources Recommend Favorite

Final results of a phase II study of nab-paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer

By Lobo Christopher   Lopes Gilberto   Baez Odalys   Castrellon Aurelio   Ferrell Annapoorna   Higgins Connie   Hurley Erin   Hurley Judith   Reis Isildinha   Richman Stephen   Seo Pearl   Silva Orlando   Slingerland Joyce   Tukia Keleni   Welsh Catherine   Glück Stefan  

Breast Cancer Research and Treatment, Vol. 123, Iss. 2, 2010-09 ,pp. : 427-435

Springer Publishing Company

Access to resources Recommend Favorite

Trastuzumab emtansine in the treatment of HER-2-positive metastatic breast cancer patients

By Bighin Claudia   Pronzato Paolo   Del Mastro Lucia  

Future Oncology, Vol. 9, Iss. 7, 2013-07 ,pp. : 955-957

Future Medicine

Access to resources Recommend Favorite

Effect of PREDICT on chemotherapy/trastuzumab recommendations in HER2positive patients with earlystage breast cancer

By  

Oncology Letters, Vol. 8, Iss. 6, 2014-01 ,pp. : 2757-2761

Spandidos Publications

Access to resources Recommend Favorite